Tarek M.A. Abdel-Fatah
SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment
Abdel-Fatah, Tarek M.A.; Broom, Reuben J.; Lu, Jun; Moseley, Paul M.; Huang, Baiqu; Li, Lili; Liu, Suling; Chen, Longxin; Ma, Runlin Z; Cao, Wenming; Wang, Xiaojia; Li, Yan; Perry, Jo K.; Aleskandarany, Mohammed; Nolan, Christopher C; Rakha, Emad A; Lobie, Peter E; Chan, Stephen Y.T.; Ellis, Ian O; Hwang, Le-Ann; Lane, David P; Green, Andrew R; Liu, Dong-Xu
Authors
Reuben J. Broom
Jun Lu
Paul M. Moseley
Baiqu Huang
Lili Li
Suling Liu
Longxin Chen
Runlin Z Ma
Wenming Cao
Xiaojia Wang
Yan Li
Jo K. Perry
Mohammed Aleskandarany
Christopher C Nolan
EMAD RAKHA Emad.Rakha@nottingham.ac.uk
Professor of Breast Cancer Pathology
Peter E Lobie
Stephen Y.T. Chan
Professor IAN ELLIS IAN.ELLIS@NOTTINGHAM.AC.UK
Professor of Cancer Pathology
Le-Ann Hwang
David P Lane
ANDREW GREEN andrew.green@nottingham.ac.uk
Associate Professor
Dong-Xu Liu
Abstract
BACKGROUND: SHON nuclear expression (SHON-Nuc+) was previously reported to predict clinical outcomes to tamoxifen therapy in ER?+ breast cancer (BC). Herein we determined if SHON expression detected by specific monoclonal antibodies could provide a more accurate prediction and serve as a biomarker for anthracycline-based combination chemotherapy (ACT).
METHODS: SHON expression was determined by immunohistochemistry in the Nottingham early-stage-BC cohort (n=1,650) who, if eligible, received adjuvant tamoxifen; the Nottingham ER?- early-stage-BC (n=697) patients who received adjuvant ACT; and the Nottingham locally advanced-BC cohort who received pre- operative ACT with/without taxanes (Neo-ACT, n=120) and if eligible, 5-year adjuvant tamoxifen treatment. Prognostic significance of SHON and its relationship with the clinical outcome of treatments were analysed.
RESULTS: As previously reported, SHON-Nuc+ in high risk/ER?+ patients was significantly associated with a 48% death risk reduction after exclusive adjuvant tamoxifen treatment compared with SHON-Nuc- [HR(95%CI)=0.52(0.34-0.78), p=0.002]. Meanwhile, in ER?- patients treated with adjuvant ACT, SHON cytoplasmic expression (SHON-Cyto+) was significantly associated with a 50% death risk reduction compared with SHON-Cyto- [HR(95%CI)=0.50(0.34-0.73), p=0.0003]. Moreover, in patients received Neo-ACT, SHON-Nuc- or SHON-Cyto+ was associated with an increased pathological complete response (pCR) compared with SHON-Nuc+ [21% vs 4%; OR(95%CI)=5.88(1.28-27.03), p=0.012], or SHON-Cyto- [20.5% vs 4.5%; OR(95%CI)=5.43(1.18-25.03), p=0.017], respectively. After receiving Neo-ACT, patients with SHON-Nuc+ had a significantly lower distant relapse risk compared to those with SHON-Nuc- [HR(95%CI)=0.41(0.19-0.87), p=0.038], whereas SHON-Cyto+ patients had a significantly higher distant relapse risk compared to SHON-Cyto- patients [HR(95%CI)=4.63(1.05-20.39), p=0.043]. Furthermore, multivariate Cox regression analyses revealed that SHON-Cyto+ was independently associated with a higher risk of distant relapse after Neo-ACT and 5- year tamoxifen treatment [HR(95%CI)=5.08(1.13-44.52), p=0.037]. The interaction term between ER? status and SHON-Nuc+ (p=0.005), and between SHON-Nuc+ and tamoxifen therapy (p=0.007), were both statistically significant.
CONCLUSION: SHON-Nuc+ in tumours predicts response to tamoxifen in ER?+ BC while SHON-Cyto+ predicts response to ACT.
Citation
Abdel-Fatah, T. M., Broom, R. J., Lu, J., Moseley, P. M., Huang, B., Li, L., …Liu, D. (2019). SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment. British Journal of Cancer, 120(7), 728–745. https://doi.org/10.1038/s41416-019-0405-x
Journal Article Type | Article |
---|---|
Acceptance Date | Jan 25, 2019 |
Online Publication Date | Feb 28, 2019 |
Publication Date | Feb 28, 2019 |
Deposit Date | Jan 28, 2019 |
Publicly Available Date | Aug 29, 2019 |
Journal | British Journal of Cancer |
Print ISSN | 0007-0920 |
Electronic ISSN | 1532-1827 |
Publisher | Cancer Research UK |
Peer Reviewed | Peer Reviewed |
Volume | 120 |
Issue | 7 |
Pages | 728–745 |
DOI | https://doi.org/10.1038/s41416-019-0405-x |
Keywords | Cancer Research; Oncology |
Public URL | https://nottingham-repository.worktribe.com/output/1499279 |
Publisher URL | https://www.nature.com/articles/s41416-019-0405-x |
Additional Information | Received: 18 October 2018; Revised: 27 January 2019; Accepted: 29 January 2019; First Online: 28 February 2019; : D.-X.L., T.M.A.A.-F., J.K.P., J.L., B.H., S.Y.T.C., A.R.G., and I.O.E. are named inventors on a PCT patent application PCT/NZ/2013/000188 and patent applications NZ603056, NZ616981, CN201380063947, AU2013332512, EP2013846652 and US15/103581; D.-X.L. and R.Z.M. are applicants for the applications PCT/NZ/2013/000188 and NZ616981; and D.-X.L. is the applicant for the application NZ603056. The remaining authors declare no competing interests.; : The data that support the findings of this study and materials described are available from the corresponding author upon reasonable request. Some restrictions may apply.; : All patients were consented as per hospital standard of care. This study was approved by the Hospital Research and Innovations Department and the Nottingham Research Ethics Committee 2 under the title "Development of a molecular genetic classification of BC" (REC Reference No C202313).; : This work was supported by the Breast Cancer Foundation New Zealand (to D.-X.L. & R.J.B., no grant number), the New Zealand Breast Cancer Cure (to D.-X.L., no grant number), the Health Research Council of New Zealand (14/704 to D.-X.L., R.J.B., T.M.A.A.-F., J.L., A.R.G., S.Y.T.C. & I.O.E.), the Auckland Medical Research Foundation (1113022 to D-X.L.), the Margaret Morley Medical Trust (to D.-X.L., no grant number), the Maurice & Phyllis Paykel Trust (to D.-X.L., no grant number), the Kelliher Charitable Trust (to D.-X.L., no grant number), the Lottery Health Research of New Zealand (340942 to D.-X.L., I.O.E., A.R.G., S.Y.T.C. & T.M.A.A.-F.), the Biopharma Programme of the University of Auckland (to D.-X.L., no grant number), and the Shenzhen Development and Reform Commission Subject Construction Project (2017/1434 to P.E.L).; : This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0). |
Files
54154 2 Merged 1548485075
(1.9 Mb)
PDF
You might also like
Breast cancer intratumour heterogeneity: current status and clinical implications
(2018)
Journal Article
Tumour heterogeneity of breast cancer: from morphology to personalised medicine
(2018)
Journal Article